According to an analysis from the Warfarin–Aspirin Recurrent Stroke Study (WARSS), a subpopulation of ischemic stroke patients with elevated NT-proBNP concentrations of more than 750 pg/mL may benefit more from anticoagulants than antiplatelet medications13. The gene discussed is NPPB; the disease is stroke disorder.